Literature DB >> 15633226

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

Hiroshi Sakugawa1, Tomofumi Nakayoshi, Kasen Kobashigawa, Tsuyoshi Yamashiro, Tatsuji Maeshiro, Satoru Miyagi, Joji Shiroma, Akiyo Toyama, Tomokuni Nakayoshi, Fukunori Kinjo, Atsushi Saito.   

Abstract

AIM: Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), and progresses to the end stage of liver disease. Biochemical markers of liver fibrosis are strongly associated with the degree of histological liver fibrosis in patients with chronic liver disease. However, data are few on the usefulness of markers in NAFLD patients. The aim of this study was to identify better noninvasive predictors of hepatic fibrosis, with special focus on markers of liver fibrosis, type VI collagen 7S domain and hyaluronic acid.
METHODS: One hundred and twelve patients with histologically proven NAFLD were studied.
RESULTS: The histological stage of NAFLD correlated with several clinical and biochemical variables, the extent of hepatic fibrosis and the markers of liver fibrosis were relatively strong associated. The best cutoff values to detect NASH were assessed by using receiver operating characteristic analysis: type VI collagen 7S domain > or =5.0 ng/mL, hyaluronic acid > or =43 ng/mL. Both markers had a high positive predictive value: type VI collagen 7S domain, 86% and hyaluronic acid, 92%. Diagnostic accuracies of these markers were evaluated to detect severe fibrosis. Both markers showed high negative predictive values: type VI collagen 7S domain (> or =5.0 ng/mL), 84% and hyaluronic acid (> or =50 ng/mL), 78%, and were significantly and independently associated with the presence of NASH or severe fibrosis by logistic regression analysis.
CONCLUSION: Both markers of liver fibrosis are useful in discriminating NASH from fatty liver alone or patients with severe fibrosis from patients with non-severe fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15633226      PMCID: PMC4205412          DOI: 10.3748/wjg.v11.i2.255

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

Review 6.  Nonalcoholic steatohepatitis.

Authors:  S G Sheth; F D Gordon; S Chopra
Journal:  Ann Intern Med       Date:  1997-01-15       Impact factor: 25.391

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  49 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

2.  [Non-alcoholic hepatic steatosis. An update].

Authors:  Llorenç Caballería Rovira; Pere Torán Montserrat; María Antonia Auladell Llorens; Guillem Pera Blanco
Journal:  Aten Primaria       Date:  2008-08       Impact factor: 1.137

Review 3.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

5.  Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.

Authors:  Joel Z Stengel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-06

6.  Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-06-15       Impact factor: 3.199

7.  Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Iradj Maleki; Mahmood Reza Aminafshari; Tarang Taghvaei; Vahid Hosseini; Alireza Rafiei; Zhila Torabizadeh; Maryam Barzin; Elahe Orang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

8.  Prolidase and oxidative stress in chronic hepatitis C.

Authors:  Fazilet Duygu; Suda Tekin Koruk; Hasan Karsen; Nurten Aksoy; Abdullah Taskin; Melek Hamidanoglu
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

9.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

10.  Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia.

Authors:  Korakot Nganvongpanit; Akanit Itthiarbha; Siriwan Ong-Chai; Prachya Kongtawelert
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.